ALT and AST: Optimal Liver Enzyme Ranges Beyond the Lab Reference

This article is for informational purposes only and does not constitute medical advice. ALT and AST results should always be interpreted alongside your clinical history, medications, and other investigations by a qualified healthcare professional. If you have concerns about your liver health, see your GP.

ALT and AST are the two liver enzymes that appear on virtually every standard blood panel in Australia, yet most people receive them without any explanation beyond "your liver function looks fine." That sign-off is often correct, but it can also mask meaningful trends — particularly early fatty liver disease — that show up well within the reference range on a conventional report but are abnormal by functional standards.

Understanding what these enzymes actually measure, where the reference ranges come from, how the ratio between them guides diagnosis, and what reversibility looks like gives you substantially more signal from a test you are already having.

What ALT Is

Alanine aminotransferase (ALT) is an enzyme found predominantly in hepatocytes — the main functional cells of the liver. Its job is to catalyse the transfer of an amino group from alanine to alpha-ketoglutarate as part of amino acid metabolism. Because ALT is concentrated inside liver cells, its concentration in the bloodstream is normally very low. When hepatocytes are damaged or their membranes become permeable — from inflammation, toxin exposure, fat accumulation, or viral injury — ALT leaks into the circulation and levels rise.

This anatomy makes ALT the most liver-specific of the two enzymes. A significant elevation almost always means something is happening to hepatocytes specifically, rather than to the broader body. It is the single most useful first-line marker for hepatocellular damage.

What AST Is

Aspartate aminotransferase (AST) catalyses a similar transamination reaction but is distributed far more widely across body tissues. It is found in the liver, but also in cardiac muscle, skeletal muscle, kidneys, brain, and red blood cells. This distribution means an elevated AST is less specific to the liver than an elevated ALT.

This distinction has real clinical value. When both enzymes are elevated, the liver is almost certainly involved. When AST rises in isolation — particularly after a hard training session, a cardiac event, or rhabdomyolysis — the source may have nothing to do with the liver at all.

The Reference Range Problem

The conventional upper limits of normal for Australian pathology laboratories — as published on ptex.au, the Australasian evidence-based pathology reference linked from the Australian Government's My Health Record — are 5–40 U/L for ALT (men) and 5–35 U/L for ALT (women), with AST at 5–35 U/L (men) and 5–30 U/L (women). These represent common reference intervals that all Australian laboratories should be using.

The problem with these numbers is how they were derived. Reference ranges in pathology are conventionally set using the 95th percentile of a reference population — people who present as healthy and are not under active investigation for disease. In populations with high rates of metabolic syndrome, insulin resistance, and non-alcoholic fatty liver disease, those 95th percentile values are shifted upward. A reference population that includes people with undiagnosed fatty liver will produce a reference range that normalises early fatty liver.

Functional medicine and integrative hepatology literature generally targets ALT below 25 to 30 U/L and AST below 20 to 25 U/L as genuinely optimal — values associated with low metabolic disease burden in prospective studies. A result of 48 U/L for ALT technically sits within most labs' reference range but by functional targets represents a meaningful signal worth investigating.

This is not a fringe position. Several large epidemiological studies — including work from the NHANES datasets — have shown that all-cause mortality risk curves for ALT begin rising well below conventional upper limits of normal.

Causes of ALT Elevation

Non-Alcoholic Fatty Liver Disease

NAFLD is the most common cause of mildly elevated ALT in Australia, with prevalence estimates between 25 and 30 percent of the adult population. Fat accumulation in hepatocytes causes low-grade inflammation (non-alcoholic steatohepatitis, or NASH, in its more progressive form) that releases ALT into the bloodstream.

NAFLD-related ALT elevation is tightly coupled to insulin resistance and liver fat accumulation. High circulating insulin promotes de novo lipogenesis in the liver. This is why ALT can be a useful surrogate metabolic marker even before glucose or insulin levels become overtly abnormal.

Alcohol

Alcohol damages hepatocytes through direct toxicity, oxidative stress, and mitochondrial injury. In alcoholic liver disease, AST typically rises more than ALT — a key distinguishing feature discussed further in the ratio section below. Even moderate alcohol intake of three to four standard drinks per day can chronically elevate both enzymes in susceptible individuals.

Viral Hepatitis

Acute hepatitis A or B can cause dramatic ALT elevations — often 10 to 40 times the upper limit of normal — as the immune response destroys infected hepatocytes. This scale of elevation is distinctly different from the mild to moderate elevations seen in metabolic liver disease. Chronic hepatitis C typically causes more modest, fluctuating elevations.

Medications

A significant and commonly overlooked cause of mildly elevated liver enzymes is medication use. Statins, NSAIDs (including ibuprofen and diclofenac), paracetamol (especially at higher doses or with concurrent alcohol), some antibiotics (particularly augmentin and flucloxacillin), and antifungals can all raise ALT. Before assuming intrinsic liver disease, reviewing the medication list is mandatory. Many mild elevations resolve completely once the offending drug is stopped.

Vigorous Exercise

Because AST is present in skeletal muscle, intense or prolonged exercise — particularly resistance training, long-distance running, or any activity causing significant muscle damage — can raise AST by two to three times the upper limit of normal. ALT rises less dramatically, since its concentration in muscle is lower. A markedly elevated AST in an otherwise well person who trained hard the day before is frequently exercise-related rather than hepatic.

Thyroid Disease

Hypothyroidism can mildly raise both ALT and AST through reduced clearance of circulating enzymes and direct effects on hepatic lipid metabolism. It is a commonly missed contributor, particularly in women. Checking TSH alongside liver enzymes when the cause is unclear is straightforward and low-cost.

The ALT/AST Ratio: Pattern Recognition in Practice

The ratio between AST and ALT — often called the De Ritis ratio — provides clinically useful pattern recognition beyond the absolute values.

Ratio below 1 (ALT greater than AST): When ALT exceeds AST, the injury pattern is consistent with hepatocellular disease where the primary insult is to liver parenchyma. NAFLD and viral hepatitis typically produce this pattern. The liver has a higher concentration of ALT than AST relative to other tissues, so predominant hepatocyte damage releases proportionally more ALT.

Ratio above 2 (AST more than twice ALT): An AST:ALT ratio above 2:1 is a classic indicator of alcoholic liver disease. Alcohol causes disproportionate AST release through mitochondrial injury and also reduces pyridoxal-5-phosphate (vitamin B6), which ALT requires as a cofactor more than AST does. A 2:1 AST:ALT ratio in the context of alcohol use history is strongly suggestive of alcoholic hepatitis.

Elevations above ten times the upper limit of normal: This magnitude of elevation — regardless of ratio — suggests acute hepatitis (viral, autoimmune, or ischaemic), severe drug-induced liver injury, or acute biliary obstruction causing hepatocellular injury. These findings require urgent medical investigation rather than watchful waiting.

GGT as the Third Marker

ALT and AST interpretation benefits substantially from a concurrent GGT and gamma-glutamyl transferase result. GGT is a membrane enzyme elevated by alcohol use, bile duct disease, fatty liver disease, and enzyme-inducing medications. Its pattern alongside ALT and AST helps distinguish:

• Isolated ALT elevation with normal GGT — more likely metabolic or exercise-related
• ALT elevation with raised GGT — consistent with fatty liver or alcohol
• GGT elevation with normal ALT and AST — can indicate bile duct irritation or medication effect without significant hepatocellular damage

GGT is also an independent cardiovascular and metabolic risk marker, making it worth reviewing alongside the transaminases rather than in isolation.

Trend Over Time: When a Single Reading Is Not Enough

A single mildly elevated ALT (1.5 to 2 times the upper limit of normal) is not automatically alarming, but it is not ignorable either. The appropriate response depends heavily on context.

If there are obvious reversible causes — recent heavy alcohol consumption, a new medication, or intense exercise in the 48 hours before the test — the evidence-based approach is to remove the suspected cause and repeat the test at four to six weeks. A transient elevation that normalises tells you the cause was situational.

Persistent elevation at repeat testing warrants a liver ultrasound to assess for steatosis or structural abnormalities, hepatitis B surface antigen and hepatitis C antibody serology, and a review of metabolic markers including fasting glucose and insulin.

Emerging research on hepatic recovery protocols — including liver health peptide research — suggests that even in established fatty liver disease, the liver retains substantial regenerative capacity when underlying metabolic drivers are addressed. This tracks with what is observed clinically in patients who make meaningful lifestyle changes.

What Reversibility Looks Like

The liver has exceptional regenerative capacity, and NAFLD-related enzyme elevation is one of the more reversible abnormalities in metabolic medicine when the underlying drivers are addressed.

The strongest intervention evidence comes from weight loss. A reduction of 5 to 10 percent of body weight in overweight individuals with fatty liver reliably normalises ALT in the majority of cases within three to six months. Reduced dietary fructose and ultra-processed carbohydrates — the primary drivers of hepatic de novo lipogenesis — produces measurable ALT improvements even without significant weight change.

Regular aerobic exercise of 150 to 200 minutes per week reduces intrahepatic fat content independently of body weight. Abstinence or significant reduction in alcohol use can produce dramatic falls in both AST and GGT within four to eight weeks.

The clinical message is that an elevated ALT in the context of metabolic disease is a genuine biological early warning, but it is also a marker that responds well to lifestyle modification — often faster than patients expect.

SHBG as a Complementary Liver Marker

SHBG as a liver-sensitive marker is worth tracking alongside transaminases in metabolic liver disease. Sex hormone binding globulin is synthesised exclusively in the liver and is suppressed by insulin and hepatic fat accumulation. A low SHBG in a person with borderline ALT elevation adds convergent evidence for underlying insulin resistance and fatty liver, even when ALT alone might be dismissed as mildly borderline.

Testing in Australia

ALT and AST are part of the liver function test (LFT) panel ordered by GPs and specialists. LFTs are covered under Medicare (MBS item 66500 when clinically indicated) and are processed by all major Australian pathology providers including Sonic Healthcare, Laverty Pathology, and Sullivan Nicolaides Pathology. Results are typically returned within 24 hours for standard samples.

For a patient-focused explanation of what your LFT results mean, ptex.au — the Australasian pathology reference linked from Australia's My Health Record system — provides plain-English summaries of all standard liver markers alongside their reference intervals.

Most LFT panels also include alkaline phosphatase (ALP), GGT, bilirubin (total and direct), and albumin — providing the full hepatic context needed to distinguish hepatocellular patterns from cholestatic patterns. If your GP orders an LFT, you are receiving all of these markers simultaneously.

Reading Your Results in Practice

When reviewing your own ALT and AST results, the most useful questions to ask are:

• Are both enzymes elevated, or just one?
• What is the AST:ALT ratio?
• Are there obvious contributing factors (alcohol, new medications, recent intense training)?
• Has the result changed compared to previous panels?
• What does the rest of the LFT panel — particularly GGT, ALP, and bilirubin — show?

A mildly elevated ALT sitting at 35 to 45 U/L with a ratio below 1 in a person who is overweight, insulin-resistant, or a regular alcohol drinker is almost certainly early metabolic liver disease, not a diagnosis that requires a hepatology referral. But it is equally not something to dismiss as "normal." Functional targets (ALT below 25 to 30 U/L, AST below 20 to 25 U/L) exist precisely because the population-derived reference range has normalised a metabolic epidemic.

The goal is not to treat a number but to understand what the number is telling you about underlying biology — and to act on that information before it progresses.